Daily Sepsis Research Analysis
Mechanistic and clinical advances in sepsis highlight a microbiota–host–pathogen axis and evolving vasoactive adjuncts. A Nature Microbiology study reveals that the siderophore enterobactin suppresses microbiota-derived AhR signaling to worsen sepsis, while a double-blind RCT suggests methylene blue expedites vasopressor liberation, and a multicenter cohort links earlier vasopressin to lower mortality.
Summary
Mechanistic and clinical advances in sepsis highlight a microbiota–host–pathogen axis and evolving vasoactive adjuncts. A Nature Microbiology study reveals that the siderophore enterobactin suppresses microbiota-derived AhR signaling to worsen sepsis, while a double-blind RCT suggests methylene blue expedites vasopressor liberation, and a multicenter cohort links earlier vasopressin to lower mortality.
Research Themes
- Microbiota–AhR–siderophore axis in sepsis pathophysiology
- Adjunctive vasoactive therapies (methylene blue, vasopressin) in septic shock
- Translational therapeutics bridging mechanism to bedside
Selected Articles
1. Enterobactin inhibits microbiota-dependent activation of AhR to promote bacterial sepsis in mice.
Gut-microbiota-derived indoles activate macrophage AhR to enhance bacterial clearance and survival in murine sepsis, while the pathogen siderophore enterobactin suppresses AhR signaling and worsens outcomes. Tryptophan supplementation restored survival, highlighting a microbiota–host–pathogen tug-of-war over AhR.
Impact: This work defines a novel, targetable axis—microbiota metabolites vs pathogen siderophores—governing sepsis survival via AhR. It opens avenues for AhR-directed or microbiome-based interventions.
Clinical Implications: While preclinical, the data suggest preserving microbiota-derived AhR agonists (e.g., through antimicrobial stewardship, nutrition) and exploring AhR agonists or strategies that neutralize siderophores. Translation to human sepsis requires careful clinical studies.
Key Findings
- Fecal microbiota transplantation and tryptophan metabolites (indoles) increased survival in Serratia marcescens sepsis.
- Macrophage-specific AhR deletion impaired bacterial clearance and survival, indicating a causal role for AhR.
- Culture supernatants from multiple pathogens inhibited AhR activation in vitro.
- Enterobactin, a secreted siderophore, inhibited AhR activation and increased sepsis mortality in vivo.
- Oral or systemic tryptophan supplementation improved survival.
Methodological Strengths
- Integrated approaches: microbiota analysis, FMT, antibiotic perturbation, and cecal metabolomics
- In vivo validation with macrophage-specific AhR knockout and survival endpoints
Limitations
- Findings are limited to murine models and selected pathogens; human applicability is unproven
- Specific dosing and timing of tryptophan may not translate directly to clinical practice
Future Directions: Test pharmacologic AhR agonists or siderophore-targeting strategies in diverse preclinical sepsis models, and evaluate AhR-related metabolite biomarkers and dietary modulation in human cohorts.
Sepsis is a major cause of morbidity and mortality, but our understanding of the mechanisms underlying survival or susceptibility is limited. Here, as pathogens often subvert host defence mechanisms, we hypothesized that this might influence the outcome of sepsis. We used microbiota analysis, faecal microbiota transplantation, antibiotic treatment and caecal metabolite analysis to show that gut-microbiota-derived tryptophan metabolites including indoles increased host survival in a mouse model of Serratia marcescens sepsis. Infection in macrophage-specific aryl hydrocarbon receptor (AhR) knockout mice revealed that AhR activation induced transcriptional reprogramming in macrophages and increased bacterial clearance and host survival. However, culture supernatants from multiple bacterial pathogens inhibited AhR activation in vitro. We showed that the secreted siderophore, enterobactin, inhibited AhR activation in vitro and increased sepsis mortality in vivo. By contrast, oral or systemic tryptophan supplementation increased survival. These findings show that sepsis survival depends upon the interplay between pathogen inhibition and the activation of AhR by a microbiota-derived metabolite.
2. Comparative study between high and low dose methylene blue infusion in septic cancer patients: a randomized, blinded, controlled study.
In a double-blind RCT of 90 cancer patients with septic shock, adjunctive methylene blue (1 or 4 mg/kg bolus plus infusion) shortened time to vasopressor discontinuation, increased vasopressor-free days, and reduced norepinephrine dose versus placebo. The 4 mg/kg bolus showed a protective association with mortality.
Impact: Randomized, blinded clinical evidence supports methylene blue as a feasible adjunct to expedite reversal of vasoplegia in septic shock, with a signal toward survival benefit.
Clinical Implications: Consider early adjunctive methylene blue for refractory vasoplegia in septic shock within clinical trials or protocols, especially where norepinephrine requirements remain high. Screen for contraindications (e.g., G6PD deficiency, serotonergic drugs) and monitor for interference with pulse oximetry.
Key Findings
- Methylene blue (1 or 4 mg/kg bolus + 72 h infusion) reduced time to vasopressor discontinuation versus placebo.
- Vasopressor-free days at 28 days increased and norepinephrine doses were lower with methylene blue.
- No significant difference between 1 mg/kg and 4 mg/kg for primary endpoints; safety acceptable with no significant adverse effects.
- The 4 mg/kg bolus was associated with lower mortality (HR 0.29, 95% CI 0.09-0.90) versus placebo.
Methodological Strengths
- Randomized, double-blind, controlled design with prospective registration
- Clinically meaningful endpoints (vasopressor discontinuation time, vasopressor-free days)
Limitations
- Single-disease context (cancer patients) with modest sample size limits generalizability
- Mortality was a secondary outcome with borderline significance; trial not powered for survival
Future Directions: Conduct adequately powered multicenter RCTs across heterogeneous septic shock populations to confirm survival benefit, define optimal dosing, and refine patient selection (e.g., vasoplegic phenotype).
PURPOSE: Septic shock is a common threat, and is the primary cause of death in almost all critical care units. Mortality of septic shock remains exceedingly high. The early use of methylene blue (MB) in different doses as adjunctive to vasopressors has promising results. METHODS: This double-blind, randomized, controlled trial comprised 90 patients divided into 3 groups: Group A received a 100 ml 0.9% NaCl placebo over 20 min; Group B received an MB bolus of 1 mg/kg in 100 ml 0.9% NaCl, and Group C received MB bolus of 4 mg/kg in 100 ml 0.9% NaCl during the same period. Groups B and C were given a 0.25 mg/kg/hour infusion of MB for 72 h after the bolus dose. All patients were started on noradrenaline at an infusion rate of 0.1-0.2 µ/kg/min and were adjusted accordingly to maintain MAP ≥ 65 mmHg. Time of vasopressor discontinuation was the primary outcome while total doses of vasopressors, ventilation days, vasopressors free days, total ICU stay, total hospital stay, and mortality rate were the secondary outcomes. RESULTS: Groups B and C exhibited significantly decreased time to vasopressor termination, and vasopressor-free days at 28 days in comparison to Group A. However, there was no significant difference between Groups B and C. Groups B and C had significantly lower noradrenaline dosages compared to Group A, however, no significant difference between Group B and Group C was found. The difference between the three groups in mortality rate was near statistical significance (p = 0.083). Using the logistic regression model, the 4 mg/kg group was protective against mortality with a hazard ratio of 0.29 (95%CI: 0.09-0.90). CONCLUSION: In cancer patients with septic shock, early adjunctive MB delivery reduces the time to a vasopressor stoppage and increases the vasopressor-free days. No significant difference between high and low MB bolus doses, and no significant adverse effects were noted. Compared to placebo, the 4 mg/kg bolus dose shows a survival advantage. TRIAL REGISTRATION: Prospectively registered at clinicaltrials.gov [NCT06005558]. (Date of registration 15/08/2023).
3. Timing of adjunctive vasopressin initiation for septic shock patients and hospital mortality: A multicentre observational study.
Across 2747 septic shock patients, initiating vasopressin within 6 hours of vasopressor start was independently associated with lower hospital mortality (aOR 0.69) despite higher baseline severity. Vasopressin initiation also immediately reduced norepinephrine-equivalent dose and improved physiologic trajectories.
Impact: Large multicenter data inform the bedside question of when to add vasopressin, suggesting a mortality benefit with earlier initiation and physiologic improvement.
Clinical Implications: Consider earlier adjunctive vasopressin when escalating catecholamines in septic shock, recognizing residual confounding in observational data. Findings support equipoise and design of timing-focused RCTs.
Key Findings
- Early vasopressin (≤6 h) was associated with lower hospital mortality (aOR 0.69, 95% CI 0.57-0.83).
- Vasopressin initiation led to an immediate reduction in norepinephrine-equivalent dose regardless of timing.
- Breakpoint analyses showed favorable shifts in arterial pH, lactate, heart rate, and crystalloid infusion rate (p<0.001).
- Early group had higher APACHE III, peak lactate, and creatinine, yet demonstrated better adjusted outcomes.
Methodological Strengths
- Large multicenter cohort (12 ICUs, n=2747) with adjustment for severity
- Physiologic breakpoint analyses capturing immediate treatment effects
Limitations
- Retrospective observational design with potential residual confounding and indication bias
- Single-region health system; generalizability to other settings uncertain
Future Directions: Prospective randomized trials to test early versus delayed vasopressin initiation and to identify subgroups most likely to benefit.
OBJECTIVE: The optimal timing of vasopressin initiation as an adjunctive vasopressor remains unclear. We aimed to study the association between the timing of vasopressin commencement, pre-specified physiological parameters, and hospital mortality. DESIGN: We conducted a multicentre, retrospective, observational study. SETTING: Twelve ICUs in Queensland, Australia between January 2015 and December 2021. PARTICIPANTS: Adult patients with septic shock who received vasopressin as an adjunctive vasopressor within 72 hours of ICU admission. MAIN OUTCOME: Hospital mortality. RESULTS: Overall, 2747 patients fulfilled the inclusion criteria. Of these, 1850 (67%) started vasopressin within six hours of vasopressor therapy start, while 897 (33%) started vasopressin between six hours and 72 hours. APACHE III score, peak lactate, and creatinine were higher in the early start group. Early vasopressin start was independently associated with decreased hospital mortality (aOR = 0.69, 95% CI = 0.57-0.83). Vasopressin infusion start was also associated with an immediate decrease in the noradrenaline-equivalent dose regardless of timing. There was a statistically significant favourable breakpoint at vasopressin start for the course of arterial pH, lactate, heart rate and crystalloid infusion rate (p<0.001). CONCLUSIONS: In patients with septic shock, early adjunctive vasopressin initiation was independently associated with lower hospital mortality. Vasopressin starting at any time was also associated with reduced tachycardia, acidosis, and hyperlactatemia.